FDA
- Status: approved
Continuation of boosted PI (Continuation of boosted PI) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic is the originator. The local marketing authorisation holder may differ — check the official source linked above.